Assessment of effectiveness and safety
nausea or vomiting, dyspnea, fatigue, diarrhea, MM, pain, constipation, insomnia
APPETITE LOSS, DISEASE
Diagnosis, disease stage, therapeutic efficacy, and the progression of disease were all evaluated based on the IMWG criteria.In addition, the participants completed the questionnaires of EORTC QLQ‐C30 QoL and QLQ‐MY20 questionnaires before and after therapy, which helped in assessing the change in quality of life (QoL). The EORTC QLQ‐C30 contains 30 items. These items are included the scale of Global Health QoL, 3 scales evaluating the symptoms (pain, fatigue, and nausea or vomiting), 5 scales assessing functioning of patients (physical functions, emotional functions, cognitive functions, role functioning and social functioning), and 6 items determining insomnia, dyspnea, appetite loss, constipation, diarrhea, and financial difficulties of patients. Higher scores of the functional and QoL scales represented better QoL; whereas for the symptom scale and 6 independent items, a higher score denotes poor patients' QoL. The EORTC QLQ‐MY20 is a questionnaire specifically adjusted for patients with MM, and it can supplement the QLQ‐C30 questionnaire.